Trial · NCT05795062
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | From hospital discharge date through 30 days following discharge date (from the data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Mean Number of Persistent Days | From the index date until the first of treatment discontinuation, treatment switch, or the end of follow-up, whichever occurred first (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Days | MEAN |
| PRIMARY | Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Switched From Index Treatment at Month 12 Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Median Time to Discontinuation From the Index Treatment | From initiation of index treatment post-discharge till its discontinuation (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
| PRIMARY | Median Time to Switch From the Index Treatment | From initiation of index treatment post-discharge till switch (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
| SECONDARY | Incidence Rate of Recurrent VTE Events | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Events per 100 participant-years | NUMBER |
| SECONDARY | Median Time to Recurrent VTE | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
| SECONDARY | Incidence Rate of Major Bleeding Events | From first hospitalization discharge through first major bleeding event (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Events per 100 participant-years | NUMBER |
| SECONDARY | Incidence Rate of Clinically Relevant Non-Major (CRNM) Bleeding Events | From first hospitalization discharge through first CRNM bleeding event (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Events per 100 participant-years | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05795062/outcomes